Catalent stock: buy or sell?
September 20th, 2019
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide.
Should I buy Catalent stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading strategy that matches with your character as inversor. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, Catalent stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Catalent stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we collected 8 ratings published for CTLT stock in the last 30 days. The general sentiment of these ratings is bullish for CTLT stock, with 7 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-28||Robert W. Baird||n/a||Outperform|
|2019-6-21||Jefferies Financial Group||Hold||Buy|
|2019-4-16||Jefferies Financial Group||n/a||Hold|
Catalent stock analysis
Catalent shares broke up the SMA line of 100d today and closed at $51.60, jumped a 1.90%.
Catalent crossed up the simple moving average line of 100 days today and closed at $51.60, jumped a 1.90%. CTLT is soaring again after a 3.68% correction from its last top on September 13th at $52.22. Since May when SMA100d and SMA200d crossed up, CTLT price gained $6.23 per share (13.73%). On July, CTLT hit new all time highs, pushing higher previous ATH of $57.65 recorded on July. New ATHs are usual entry points for many trading setups as there aren't higher resistences.
After sliding for 4 weeks, this week Catalent inched a slightly fine 0.49%, closing at $51.60. After 4 weeks sliding, this week raised a 0.48%. By mid August CTLT plunged a shocking -5.06% in just one week.
CTLT shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $49.93 last week. Previous top ($58.38) will play as a resistance in possible new gains. Not so far away is the last all-time high Catalent marked late July. Since mid May when SMA20w and SMA40w crossed up, CTLT price gained $6.83 per share (15.26%). By mid April CTLT price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
Catalent stock price history
Catalent IPO was on July 31st, 2014 at $20.00 per share1. Since then, CTLT stock surged a 158.00%, with an average of 31.60% per year. If you had invested right after CTLT's IPO a $1,000 in Catalent stock in 2014, it would worth $1,580.00 today.
1: Adjusted price after possible price splits or reverse-splits.
Catalent stock historical price chart
CTLT stock reached all-time highs on July with a price of $58.38.
Catalent stock price target is $56.30Nobody can reliably foresee how stock prices may evolve in the future. However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' CTLT stock price predictions in the hope that they will be met as they may be wrong and not met. We detected 8 price targets for CTLT stock posted in the last 30 days:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-28||Robert W. Baird||Raises Target||$50.00||$60.00||20%|
|2019-8-28||Morgan Stanley||Raises Target||$50.00||$61.00||22%|
|2019-7-23||UBS Group||Raises Target||n/a||$64.00||-|
|2019-6-21||Jefferies Financial Group||Upgrades||$50.00||$62.00||24%|
|2019-4-16||Morgan Stanley||Raises Target||$46.00||$50.00||8.7%|
|2019-4-16||Jefferies Financial Group||Raises Target||$44.00||$50.00||13.6%|
Financials and fundamental analysis
Earnings date and Earnings per ShareCatalent presented dazzling results for 2018-Q4 on February. Catalent boosted Earnings per Share (EPS) by 24.20%, beating analysts consensus of $0.33. Catalent posted $0.41.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, Catalent annual turnover boosted a super good 18.70% to $2,463.40 million dollars from $2,075.40 marked in 2017. However, its profit margin (compared to sales) declined to 3.39%, that is $83.60 million. To have an up to date view of the financial situation of Catalent, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Catalent TTM sales up to December 2018 were $2,488.00 and income was $136.30 M dollars. If we compare this TTM figures with the last reported annuality, we can review Catalent business evolution since June 2018: Annual turnover up to December, compared to lastest yearly report, remained constant a slightly fine 1.00%. However, profit margin (net income/revenues) grew at 3.39%.
|2013||$1,800 M||-||$-47.90 M-2.7%||-|
|2014||$1,830 M||1.67%||$19 M1.0%||-139.46%|
|2015||$1,831 M||0.04%||$212 M11.6%||1,022.75%|
|2016||$1,848 M||0.94%||$112 M6.0%||-47.46%|
|2017||$2,075 M||12.30%||$110 M5.3%||-1.52%|
|2018||$2,463 M||18.70%||$84 M3.4%||-23.86%|
|TTM||$2,488 M||1.00%||$136 M5.5%||63.04%|
Quarterly financial resultsCatalent reported $623.00 M in revenues for 2018-Q4, a 12.90% improvement compared to previous quarter. Reported quarter income marked $49.00 million with a profit margin of 7.87%. Profit margin rocketed a 10.47% compared to previous quarter when profit margin was -2.61%. When comparing turnover to same quarter last year, Catalent sales marked a slightly good increase and inched a 2.75%.
|2017-Q1||$533 M||-||$26 M4.9%||-|
|2017-Q2||$617 M||15.83%||$62 M10.0%||137.69%|
|2017-Q3||$544 M||-11.83%||$4 M0.7%||-93.85%|
|2017-Q4||$606 M||11.47%||$-22 M-3.6%||-676.32%|
|2018-Q1||$628 M||3.56%||$19 M3.0%||-186.76%|
|2018-Q2||$685 M||9.14%||$83 M12.1%||335.26%|
|2018-Q3||$552 M||-19.48%||$-14 M-2.6%||-117.41%|
|2018-Q4||$623 M||12.90%||$49 M7.9%||-440.28%|
Catalent ownershipWhen you are planning to invest in shares of a company, it's worth to check its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Catalent, 0.70% of all outstanding shares are owned by its staff.
Bearish positions for CTLT stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$7.5 B||$1.1 B||$1.1 B||$7.3 B||$1.5 B|
|Total shares||146.0 M||45.9 M||101.3 M||56.6 M||52.5 M|
|Float shares||145.0 M||36.7 M||53.5 M||55.1 M||50.7 M|
|- Institutional holdings (%)||101.7%||112.5%||81.3%||96.2%||98.9%|
|- Insider holdings (%)||0.7%||1.8%||32.5%||2.8%||3.4%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, September 20th, 2019|
|Day range||$50.84 - $51.65|
|Average true range||$1.11|
|50d mov avg||$54.07|
|100d mov avg||$51.42|
|200d mov avg||$45.09|
Catalent performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked Aerie Pharmaceuticals, Innoviva, Jazz Pharmaceuticals and Supernus Pharmaceuticals as the bechmarking frame for Catalent stock.